A low-sodium diet potentiates the effects of losartan in type 2 diabetes

Diabetes Care

Volumn 25, Issue 4, 2002, Pages 663-671

  Houlihan, Christine A ^a   Allen, Terri J ^a   Baxter, Amynta L ^a   Panangiotopoulos, Sianna ^a   Casley, David J ^a   Cooper, Mark E ^a   Jerums, George ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; LOSARTAN; PLACEBO; ALDOSTERONE; ANGIOTENSIN II; CREATININE; DIAGNOSTIC AGENT; RENIN; SODIUM;

ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; HUMAN; HYPOTENSION; KIDNEY BLOOD FLOW; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SODIUM RESTRICTION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; TIME SERIES ANALYSIS; ALBUMINURIA; BLOOD; BLOOD PRESSURE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; KIDNEY CIRCULATION; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

ALBUMINURIA; ALDOSTERONE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIET, SODIUM-RESTRICTED; DRUG SYNERGISM; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; LOSARTAN; MALE; MIDDLE AGED; PLACEBOS; RENAL CIRCULATION; RENIN; SODIUM;

EID: 0036550692     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.4.663     Document Type: Article

References (41)

1. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
2. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355:253-259, 2000
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
4. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
6. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36:272-279, 1989
7. van den Meiracker AH, Admiral PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In 't Veld AJ, et al.: Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 25:22-29, 1995
8. Jerums G, Allen TJ, Tsalamandris C, Cooper ME: Angiotensin converting enzyme inhibition and calcium channel blockers in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. Kindney Int 41:904-911, 1992
9. Allen TJ, Waldron MJ, Casley D, Jerums G, Cooper ME: Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes. Diabetes 46:19-24, 1997
10. Fabris B, Jackson B, Johnston CI: Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension 17:497-503, 1991
11. Cappuccio FP, Markandu ND, Carney C, Sagnella GA, MacGregor GA: Double-blind randomised trial of modest salt restriction in older people. Lancet 350:850-854, 1997
12. MacGregor GA, Markandu ND, Singer DR, Cappuccio FP, Shore AC, Sagnella GA: Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study. Br Med J (Clin Res Ed) 294:531-534, 1987
13. MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP: Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet 2:1244-1247, 1989
14. Beretta-Piccoli C, Weidmann P: Body sodium-blood volume state in nonazotemic diabetes mellitus. Miner Electrolyte Metab 7:36-47, 1982
15. O'Hare JA, Ferriss JB, Brady D, Twomey B, O'Sullivan DJ: Exchangeable sodium and renin in hypertensive diabetic patients with and without nephropathy. Hypertension 7:II43-II48, 1985
16. DeFronzo RA: The effect of insulin on renal sodium metabolism: a review with clinical implications. Diabetologia 21:165-171, 1981
17. De'Oliveira JM, Price DA, Fisher ND, Allan DR, McKnight JA, Williams GH, Hollenberg NK: Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 52:771-777, 1997
18. Weir MR: Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin system. Miner Electrolyte Metab 24:438-445, 1998
19. Bach LA, Sharpe K: Sample size for clinical and biological research. Aust N Z J Med 19:64-68, 1989
20. Jenkins MA, Houlihan C, Ratnaike S, Jerums G, Des Parkin J: Measurement of iohexol by capillary electrophoresis: minimizing practical problems encountered. Ann Clin Biochem 37:529-536, 2000
21. Houlihan C, Jenkins M, Osicka T, Scott A, Parkin D, Jerums G: A comparison of the plasma disappearance of iohexol and 99mTc-DTPA for the measurement of glomerular filtration rate (GFR) in diabetes. Ausi N Z J Med 29:693-700, 1999
22. Russell C: Optimum sample times for single-injection, multisample renal clearance methods. J Nucl Med 34:1761-1765, 1993
23. Russell CD, Li Y, Nadiye Kahraman H, Dubovsky EV: Renal clearance of technetium-99m-MAG3: normal values (Letter). J Nucl Med 36:706-708, 1995
24. Kimura G, Brenner BM: Indirect assessment of glomerular capillary pressure from pressure-natriuresis relationship: comparison with direct measurements reported in rats. Hypertens Res 20:143-148, 1997
25. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 328:914-921, 1993
26. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER III, Simons-Morton DG, Karanja N, Lin PH: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 344:3-10, 2001
27. Dodson PM, Beevers M, Hallworth R, Webberley MJ, Fletcher RF, Taylor KG: Sodium restriction and blood pressure in hypertensive type II diabetics: randomised blind controlled and crossover studies of moderate sodium restriction and sodium supplementation. BMJ 298:227-230, 1989
28. Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD: Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 21:704-713, 1993
29. Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al: Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 25:37-46, 1995
30. van Paassen P, de Zeeuw D, Navis G, de Jong PE: Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension? Hypertension 27:202-208, 1996
31. Buter H, Navis G, Dullaart RP, de Zeeuw D, de Jong PE: Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant 16:771-775, 2001
32. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM: Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 16:90-93, 2001
33. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601-606, 2000
34. Bohlen L, de Courten M, Weidmann P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 7:84S-92S, 1994
35. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
36. Hostetter TH: Diabetic nephropathy. Metabolic versus hemodynamic considerations. Diabetes Care 15:1205-1215, 1992
37. Cohen D, Dodds R, Viberti G: Effect of protein restriction in insulin dependent diabetics at risk of nephropathy. Br Med J (Clin Res Ed) 294:795-798, 1987
38. Bakris GL, Smith A: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 125:201-204, 1996
39. Parfrey PS, Markandu ND, Roulston JE, Jones BE, Jones JC, MacGregor GA: Relation between arterial pressure, dietary sodium intake, and renin system in essential hypertension. Br Med J (Clin Res Ed) 283:94-97, 1981
40. Singer DR, Markandu ND, Cappuccio FP, Miller MA, Sagnella GA, MacGregor GA: Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. Hypertension 25:1042-1044, 1995
41. Greenberg A: Diuretic complications. Am J Med Sci 319:10-24, 2000